STOCK TITAN
  1. Home
  2. News
  3. VRTX

Vertex Pharmaceuticals, Inc. - VRTX STOCK NEWS

Welcome to our dedicated news page for Vertex Pharmaceuticals (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vertex Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vertex Pharmaceuticals's position in the market.

News
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Rhea-AI Summary
Vertex Pharmaceuticals receives conditional marketing authorization for CASGEVY™ in the EU for treating severe sickle cell disease and transfusion-dependent beta thalassemia, potentially benefiting over 8,000 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
none
-
News
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported consolidated financial results for the fourth quarter and full year ended December 31, 2023. The company achieved full year product revenue of $9.87 billion, an 11% increase compared to 2022. They also provided full year 2024 product revenue guidance of $10.55 to $10.75 billion. CASGEVYTM was approved in the U.S., Great Britain, the Kingdom of Saudi Arabia, and Bahrain, and Vertex is on track to submit new drug applications (NDAs) to the FDA by mid-2024 for both VX-548 in Acute Pain and the Vanzacaftor Triple in CF. The company also has a broad and deep clinical-stage pipeline advancing across 10 disease areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
earnings
-
News
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announces positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor (the “vanza triple”) program, the most comprehensive Phase 3 pivotal program ever conducted for the treatment of cystic fibrosis (CF). The program included two randomized, double-blind, active-controlled, 52-week trials, SKYLINE 102 and SKYLINE 103, and a third Phase 3 single-arm, 24-week, open-label study, RIDGELINE 105. The vanza triple was generally well tolerated across all three studies. Vertex plans to file for approval with global regulators for people with CF ages 6 years and older by mid-2024, and use priority review voucher in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
none
News
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
Rhea-AI Summary
Vertex Pharmaceuticals (Nasdaq: VRTX) announced positive results from its Phase 3 program for VX-548, showing statistically significant improvement in pain compared to placebo in abdominoplasty and bunionectomy trials. VX-548 also demonstrated effectiveness in a broad range of surgical and non-surgical pain conditions for up to 14 days. The drug was safe and well-tolerated in all three studies. The company plans to submit a New Drug Application to the FDA by mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
clinical trial
-
News
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
Rhea-AI Summary
Vertex Pharmaceuticals (VRTX) will release its Q4 and full year 2023 financial results on February 5, 2024, followed by a conference call and webcast. Participants can access the call through dial-in or webcast via the company's website. An archived webcast will be available after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
earnings
-
News
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has received FDA approval for CASGEVY™, a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older. The company is establishing a network of authorized treatment centers (ATCs) throughout the U.S. to offer CASGEVY to eligible patients, with all nine ATCs activated in the U.S. able to offer CASGEVY to eligible patients with TDT and sickle cell disease (SCD).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
fda approval
News
BetterInvesting™ Magazine Update on Vertex Pharmaceuticals Inc. and Martin Marietta Materials Inc.
Rhea-AI Summary
BetterInvesting Magazine names Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) as 'Stock to Study' and Martin Marietta Materials Inc. (NYSE: MLM) as 'Undervalued Stock' in the March 2024 issue. The S&P500 Index gained over 26% in 2023, with individual stocks having a significant impact. Ken Zendel, CEO of National Association of Investors, emphasizes the importance of understanding individual stocks and their performance for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
-
News
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announces that CASGEVY™ has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Saudi Arabia. This marks the first medicine to be evaluated through the SFDA's Breakthrough Medicines Program and is Vertex's first ever regulatory approval in the Kingdom of Saudi Arabia. CASGEVY is approved for individuals 12 years and older with SCD or TDT, offering a one-time transformative therapy for these genetic blood disorders prevalent in the country.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
none
-
News
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced program updates, including strong performance in cystic fibrosis and pipeline acceleration. The company aims to bring transformative medicines to patients with serious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) CEO to Present at J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
conferences
Stock VRTX logo
Vertex Pharmaceuticals, Inc.

Nasdaq:VRTX

VRTX Rankings

#112 Ranked by Market Cap
#1118 Ranked by Stock Gains
N/A Ranked by Dividends

VRTX Stock Data

102.49B
257.56M
0.11%
97.33%
1.54%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About VRTX

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.